tailieunhanh - Combined analysis of PTEN, HER2, and hormone receptors status: Remodeling breast cancer risk profiling

Phosphatase and tensin homolog (PTEN) loss is associated with tumorigenesis, tumor progression, and therapy resistance in breast cancer. However, the clinical value of PTEN as a biomarker in these patients is controversial. We sought to determine whether the benefit of traditional biomarkers testing is improved by the analysis of PTEN status for the identification of high-risk breast cancer. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN